Table 3.
Comparison of efficacy for dabrafenib plus trametinib versus vemurafenib plus cobimetinib
| Outcome | COMBI-v | coBRIM | ITC results | |||||
|---|---|---|---|---|---|---|---|---|
| D + T | V | V | V + C | HR/RRa | LCI | UCI | p value | |
| Overall survival, median (95% CI), months | 25.6(22.6 − NR) | 18.0(15.6 − 20.7) | 17.4(15.0 − 19.8) | 22.3(20.3 − NR) | 0.94 | 0.68 | 1.30 | 0.7227 |
| Progression-free survival, median (95% CI), months | 12.6(10.7 − 15.5) | 7.3(5.8 − 7.8) | 7.2(5.6 – 7.5) | 12.3(9.5 – 13.4) | 1.05 | 0.79 | 1.40 | 0.7300 |
| Overall response rate, no./total no. (%) | 226/352(64%) | 180/352(51%) | 124/248(70%) | 172/247(50%) | 0.90 | 0.74 | 1.10 | 0.3029 |
aFor D + T versus V + C; HR is the output for time-to-event outcomes, i.e., overall survival and progression-free survival; RR is the output for overall response rate
CI confidence interval, D + T dabrafenib plus trametinib, HR hazard ratio, NR not reached, RR risk ratio, LCI lower 95% CI, UCI upper 95% CI, V vemurafenib, V + C vemurafenib plus cobimetinib